When is the next results date for Mono Pharmacare?

No Upcoming Board Meetings

Has Mono Pharmacare declared dividend?

No Dividend History Available

What is the technical trend for Mono Pharmacare?

As of May 19, 2025, Mono Pharmacare's technical trend is mildly bearish, indicated by daily moving averages and monthly Bollinger Bands, despite some conflicting signals from weekly MACD and KST.

As of 19 May 2025, the technical trend for Mono Pharmacare has changed from sideways to mildly bearish. The daily moving averages indicate a mildly bearish stance, while the weekly MACD and KST are mildly bullish, suggesting some conflicting signals. The Bollinger Bands show a bearish trend on the monthly timeframe, further supporting the bearish outlook. The stock has experienced a significant decline year-to-date and over the past year, underperforming compared to the Sensex. Overall, the current technical stance is mildly bearish, driven primarily by the daily moving averages and the monthly Bollinger Bands.

Who are the peers of the Mono Pharmacare?

Mono Pharmacare's peers include Medicamen Organ., Vilin Bio Med, ANG Lifesciences, Veerhealth Care, Chandra Bhagat, Guj. Terce Labs., Roopa Industries, Kabra Drugs, and Shree Ganesh Bio. In terms of performance, Vilin Bio Med has the highest 1-year return at 34.25%, while Mono Pharmacare's return is -34.38%.

Peers: The peers of Mono Pharmacare are Medicamen Organ., Vilin Bio Med, ANG Lifesciences, Veerhealth Care, Chandra Bhagat, Guj. Terce Labs., Roopa Industries, Kabra Drugs, and Shree Ganesh Bio.<BR><BR>Quality Snapshot: Excellent management risk is observed at Medicamen Organ., while Below Average management risk is found at Mono Pharmacare, Vilin Bio Med, ANG Lifesciences, Veerhealth Care, Chandra Bhagat, Guj. Terce Labs., Roopa Industries, and Shree Ganesh Bio. Growth is Excellent at Medicamen Organ., Good at Mono Pharmacare, and Below Average at Vilin Bio Med, ANG Lifesciences, Veerhealth Care, Chandra Bhagat, Guj. Terce Labs., Roopa Industries, and Shree Ganesh Bio. Capital Structure is Good at Veerhealth Care, Below Average at Medicamen Organ., Mono Pharmacare, Vilin Bio Med, ANG Lifesciences, Chandra Bhagat, Guj. Terce Labs., Roopa Industries, and Shree Ganesh Bio, while Kabra Drugs does not qualify.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Vilin Bio Med at 34.25%, while the peer with the lowest is Medicamen Organ. at -63.92%. Mono Pharmacare's own 1-year return is -34.38%, which is better than Medicamen Organ. but worse than Vilin Bio Med. Additionally, the six-month return is negative for Mono Pharmacare and Medicamen Organ.

What does Mono Pharmacare do?

Mono Pharmacare Ltd is a Micro Cap company focused on marketing and distributing pharmaceutical products. It transitioned from a partnership to a public limited company in October 2022, with a market cap of INR 43 Cr and key metrics including a P/E ratio of 14.00.

Overview: <BR>Mono Pharmacare Ltd is engaged in the marketing and distribution of pharmaceutical products and operates within the Pharmaceuticals & Biotechnology industry, classified as a Micro Cap company.<BR><BR>History: <BR>Mono Pharmacare Limited was originally formed as a Partnership Firm named "M/s. Mono Chemist" on May 06, 1994. It was converted into a Public Limited company on October 17, 2022, as per the Certificate of Incorporation issued by the Registrar of Companies, Ahmedabad. Revenue and profit data for the latest quarter are not available.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: N/A <BR>Most recent Net Profit: N/A <BR>Market-cap value: INR 43 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 14.00 <BR>Industry P/E: 37 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 1.46 <BR>Return on Equity: 10.99% <BR>Price to Book: 1.53 <BR><BR>Contact Details: <BR>Address: Not available <BR>Phone: Not available <BR>Email: Not available <BR>Website: Not available

Who are the top shareholders of the Mono Pharmacare?

The top shareholder of Mono Pharmacare is Lakhatariya Panilam, holding 45.43% of the shares. The highest public shareholder is Harshad Rasiklal Sheth at 3.68%, while individual investors collectively own 35.6%.

The top shareholders of Mono Pharmacare include the promoters, with Lakhatariya Panilam holding the largest share at 45.43%. There are no pledged promoter holdings, and mutual funds and foreign institutional investors do not hold any shares in the company. The highest public shareholder is Harshad Rasiklal Sheth, who owns 3.68%. Additionally, individual investors collectively hold 35.6% of the shares.

How big is Mono Pharmacare?

As of 23rd July, Mono Pharmacare Ltd has a market capitalization of 42.00 Cr, classifying it as a Micro Cap company. The latest financial data for the past four quarters is unavailable, but for the annual period ending March 2024, it reports Shareholder's Funds of 28.11 Cr and Total Assets of 81.10 Cr.

As of 23rd July, Mono Pharmacare Ltd has a market capitalization of 42.00 Cr, categorizing it as a Micro Cap company.<BR><BR>There is no valid financial data available for the latest four quarters, including Net Sales and Net Profit figures.<BR><BR>For the latest annual period ending in March 2024, the company reports Shareholder's Funds of 28.11 Cr and Total Assets of 81.10 Cr.

Is Mono Pharmacare overvalued or undervalued?

As of November 10, 2025, Mono Pharmacare is considered overvalued with a valuation grade of expensive, reflected by its PE Ratio of 11.72 and underperformance of 43.84% compared to the Sensex's 5.91% gain, especially when compared to peers like Sun Pharma and Cipla.

As of 10 November 2025, the valuation grade for Mono Pharmacare has moved from very expensive to expensive. The company is currently considered overvalued based on its financial ratios. Key ratios include a PE Ratio of 11.72, an EV to EBITDA of 11.68, and a PEG Ratio of 0.44, which indicates potential growth at a reasonable price compared to its earnings.<BR><BR>When comparing Mono Pharmacare to its peers, Sun Pharma has a significantly higher PE Ratio of 35.15, while Cipla, which is rated attractive, has a PE Ratio of 22.45. This suggests that Mono Pharmacare's valuation is not justified when looking at the broader industry context, especially given its recent stock performance, which has underperformed the Sensex over the past year, with a decline of 43.84% compared to the Sensex's gain of 5.91%.

How has been the historical performance of Mono Pharmacare?

Mono Pharmacare exhibited strong financial growth from March 2024 to March 2025, with net sales rising from 122.34 Cr to 168.34 Cr and profit after tax increasing from 2.46 Cr to 3.11 Cr, despite ongoing negative cash flow from operating activities. Total liabilities and debt also increased, but current assets improved, indicating better liquidity.

Answer:<BR>The historical performance of Mono Pharmacare shows a positive trend in key financial metrics from March 2024 to March 2025.<BR><BR>Breakdown:<BR>Mono Pharmacare's net sales increased significantly from 122.34 Cr in March 2024 to 168.34 Cr in March 2025, reflecting a robust growth in total operating income, which also rose to 168.34 Cr from 122.34 Cr. The total expenditure, excluding depreciation, rose to 160.71 Cr from 116.01 Cr, primarily driven by higher purchases of finished goods and other expenses. Operating profit, excluding other income, improved to 7.63 Cr from 6.33 Cr, leading to an overall operating profit of 8.61 Cr compared to 6.43 Cr the previous year. Profit before tax increased to 4.46 Cr from 3.23 Cr, and profit after tax rose to 3.11 Cr from 2.46 Cr. The consolidated net profit also saw an increase to 3.09 Cr from 2.44 Cr, with earnings per share growing to 1.75 from 1.38. On the balance sheet, total liabilities increased to 110.01 Cr from 81.10 Cr, with total debt rising to 53.56 Cr from 41.44 Cr. Current assets also grew significantly to 108.99 Cr from 80.16 Cr, indicating improved liquidity. However, cash flow from operating activities remained negative at -4.00 Cr, though it was an improvement from -8.00 Cr the previous year. Overall, Mono Pharmacare demonstrated strong revenue growth and profitability improvements, despite challenges in cash flow management.

Which are the latest news on Mono Pharmacare?

Why is Mono Pharmacare falling/rising?

As of 21-Dec, Mono Pharmacare Ltd's stock price is at 16.50, unchanged from the previous day, and has significantly underperformed with a 52.38% decline year-to-date. The stock is trading below all key moving averages, indicating a consistent downward trend and decreased investor participation.

As of 21-Dec, Mono Pharmacare Ltd's stock price is currently at 16.50, with no change from the previous day. The stock has been underperforming significantly, with a decline of 7.30% over the past week and 16.24% over the past month. Year-to-date, the stock has fallen by 52.38%, contrasting sharply with the Sensex, which has gained 9.82% during the same period. <BR><BR>Today's performance indicates that Mono Pharmacare has underperformed its sector by 0.75%. Additionally, the stock is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, suggesting a consistent downward trend. Investor participation has also decreased, with a delivery volume of only 2,000 shares on December 18, which represents a significant drop of 72.22% compared to the 5-day average delivery volume. <BR><BR>Overall, the combination of declining stock performance, lower investor participation, and trading below moving averages indicates that Mono Pharmacare's stock is currently falling.

Why is Mono Pharmacare falling/rising?

As of 22-Dec, Mono Pharmacare Ltd's stock price is Rs. 15.70, reflecting a 4.85% decrease and a significant decline over various periods, including a 54.69% drop year-to-date. The stock has reached a new 52-week low and is underperforming its sector, indicating a persistent downward trend.

As of 22-Dec, Mono Pharmacare Ltd's stock price is falling, currently at Rs. 15.70, which reflects a decrease of Rs. 0.8 or 4.85%. This decline is evident in the stock's performance over various periods, showing a significant drop of 7.92% over the past week and 23.60% over the past month. Year-to-date, the stock has plummeted by 54.69%, while it has decreased by 51.09% over the past year, contrasting sharply with the Sensex, which has gained 10.69% in the same timeframe.<BR><BR>Today's trading activity indicates that the stock has hit a new 52-week and all-time low of Rs. 15.70. Furthermore, it has underperformed its sector by 5.5% today and is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, suggesting a persistent downward trend. Additionally, there has been a notable decline in investor participation, with delivery volume dropping by 72.22% compared to the 5-day average. These factors collectively contribute to the ongoing decline in Mono Pharmacare's stock price.

Why is Mono Pharmacare Ltd falling/rising?

As of 23-Dec, Mono Pharmacare Ltd's stock price is Rs. 14.95, reflecting a 4.78% decline. The stock has significantly underperformed, with a year-to-date decrease of 56.85% and hitting a new all-time low, indicating waning investor confidence.

As of 23-Dec, Mono Pharmacare Ltd's stock price is falling, currently at Rs. 14.95, which reflects a decrease of Rs. 0.75 or 4.78%. This decline is evident in the stock's performance over various periods, showing a significant drop of 12.32% over the past week and 27.25% over the past month. Year-to-date, the stock has decreased by 56.85%, contrasting sharply with the Sensex, which has gained 10.71% during the same timeframe.<BR><BR>Today's performance indicates that the stock has underperformed its sector by 4.57%. Additionally, it has hit a new 52-week and all-time low of Rs. 14.95. The stock is also trading below its moving averages across various timeframes, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, which typically signals a bearish trend.<BR><BR>Despite a slight increase in investor participation, with delivery volume rising by 11.11% against the 5-day average, the overall sentiment remains negative. The liquidity of the stock is adequate for trading, but the persistent decline in price and underperformance against the benchmark suggest that investor confidence is waning.

Why is Mono Pharmacare Ltd falling/rising?

As of 24-Dec, Mono Pharmacare Ltd's stock price is currently at Rs. 15.20, showing a slight increase today but has experienced significant declines over the past year, with a year-to-date drop of 56.13%. Despite today's positive movement and increased investor interest, the stock remains below its moving averages, indicating a bearish trend.

As of 24-Dec, Mono Pharmacare Ltd's stock price is rising, currently at Rs. 15.20, reflecting an increase of Rs. 0.25 or 1.67%. Despite this positive movement today, the stock has faced significant declines over longer periods, with a year-to-date drop of 56.13% and a one-year decline of 53.94%. <BR><BR>Today's performance shows that the stock has outperformed its sector by 2.1%, which may indicate a temporary positive sentiment among investors. Additionally, there has been a notable increase in investor participation, with delivery volume rising by 90.48% compared to the five-day average, suggesting heightened interest in trading the stock. <BR><BR>However, it is important to note that Mono Pharmacare is trading below its moving averages across various time frames, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, which typically indicates a bearish trend. Furthermore, the stock hit a new 52-week low of Rs. 14.5 earlier today, which could contribute to ongoing concerns about its long-term performance. <BR><BR>In summary, while there is a slight rise in the stock price today, the overall trend remains negative due to substantial declines over the past year and the stock's position relative to its moving averages.

Why is Mono Pharmacare Ltd falling/rising?

As of 25-Dec, the stock price of Mono Pharmacare Ltd is rising by 1.67% today, but it has seen significant declines of over 53% year-to-date and is trading below its moving averages, indicating a bearish trend despite today's performance.

As of 25-Dec, the stock price of Mono Pharmacare Ltd is rising, as indicated by a change of 0.25, or 1.67%, from the previous trading session. Despite this increase, it is important to note that the stock has experienced significant declines over various time periods, with a year-to-date drop of 56.13% and a one-year decline of 53.94%. <BR><BR>Today's performance shows that the stock has outperformed its sector by 2.1%, which may contribute to the positive movement in its price. Additionally, there has been a notable increase in investor participation, with a delivery volume of 16,000 shares on December 23, representing a 90.48% rise compared to the 5-day average delivery volume. <BR><BR>However, the stock is currently trading below its moving averages across multiple time frames, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, indicating a generally bearish trend. Furthermore, the stock hit a new 52-week low of Rs. 14.5 earlier today, which reflects ongoing challenges despite the recent uptick in price. <BR><BR>In summary, while Mono Pharmacare Ltd's stock price is experiencing a rise today, it is essential to consider the broader context of its significant declines over time and its current trading position relative to moving averages.